PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Mar 2, 2011
SOUTH PLAINFIELD, NJ – March 2, 2011 – PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The research marks a milestone in PTC's collaboration with the Wellcome ...
Feb 1, 2011
SOUTH PLAINFIELD, NJ AND HACKENSACK, NJ – FEBRUARY 1, 2011 – PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy (DBMD). PPMD has awarded PTC a $250,000 grant, with the potential of add...
Jan 19, 2011
SOUTH PLAINFIELD, NJ – January 19, 2011 – Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science. AAAS Fellows are chosen by their peers and r...
Dec 21, 2010
SOUTH PLAINFIELD, NJ – DECEMBER 21, 2010 – PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF).The 48-week study is designed to determine whether ataluren can improve lung function...
Dec 1, 2010
SOUTH PLAINFIELD, NJ – December 1, 2010 – Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a clinically meaningful endpoint in dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (DBMD). The data showed that boys with...
Nov 15, 2010
SOUTH PLAINFIELD, NJ – November 15, 2010 – PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine. The published data show that treatment with ataluren, an investig...
Oct 26, 2010
SOUTH PLAINFIELD, NJ – October 26, 2010 – PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia (nmMMA). MMA is a rare genetic disorder caused by deficiencies of crucial metabolic enz...
Oct 15, 2010
SOUTH PLAINFIELD, NJ – October 15, 2010 – PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD)....
Sep 21, 2010
SOUTH PLAINFIELD, NJ – SEPTEMBER 21, 2010 – PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). The g...
Jun 7, 2010
SOUTH PLAINFIELD, NJ – June 7, 2010 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5.4 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers. Bmi-1 has been implicated in a wide variety...
Page: FirstPrevious ...
23
NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue